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Abstract
Background: Cancer patients have a highly increased risk of psychiatric disorders following diagnosis, compared
with cancer-free individuals. Inflammation is involved in the development of both cancer and psychiatric disorders.
The role of non-steroidal anti-inflammatory drugs (NSAIDs) in the subsequent risk of psychiatric disorders after
cancer diagnosis is however unknown.
Methods: We performed a cohort study of all patients diagnosed with a first primary malignancy between July
2006 and December 2013 in Sweden. Cox proportional hazards models were used to assess the association of NSAI
D use during the year before cancer diagnosis with the risk of depression, anxiety, and stress-related disorders
during the first year after cancer diagnosis.
Results: Among 316,904 patients identified, 5613 patients received a diagnosis of depression, anxiety, or stress-
related disorders during the year after cancer diagnosis. Compared with no use of NSAIDs, the use of aspirin alone
was associated with a lower rate of depression, anxiety, and stress-related disorders (hazard ratio [HR], 0.88; 95%
confidence interval [CI], 0.81 to 0.97), whereas the use of non-aspirin NSAIDs alone was associated with a higher
rate (HR, 1.24; 95% CI, 1.15 to 1.32), after adjustment for sociodemographic factors, comorbidity, indications for NSAI
D use, and cancer characteristics. The association of aspirin with reduced rate of depression, anxiety, and stress-
related disorders was strongest for current use (HR, 0.84; 95% CI, 0.75 to 0.93), low-dose use (HR, 0.88; 95% CI, 0.80
to 0.98), long-term use (HR, 0.84; 95% CI, 0.76 to 0.94), and among patients with cardiovascular disease (HR, 0.81;
95% CI, 0.68 to 0.95) or breast cancer (HR, 0.74; 95% CI, 0.56 to 0.98).
Conclusion: Pre-diagnostic use of aspirin was associated with a decreased risk of depression, anxiety, and stress-
related disorders during the first year following cancer diagnosis.
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Background
Psychiatric disorders are common comorbidities among
patients with cancer [1] and may contribute to increased
morbidity [2] and mortality [3, 4] after cancer diagnosis.
In a previous study, we reported a highly increased risk
of common psychiatric disorders, including depression,
anxiety, and stress-related disorders, namely post-
traumatic stress disorder (PTSD), acute stress reaction,
adjustment disorder, and other stress reactions, among
cancer patients, especially during the first year after can-
cer diagnosis [5]. Underlying reasons for such increased
risk may include a severe stress response after receiving
cancer diagnosis [6–8] and psychiatric symptoms caused
by cancer treatment [9, 10], pain [11], and inflammation
[12, 13]. Inflammation in the tumor micro-environment
drives tumor development and progression [14] and can-
cer patients have a high burden of cancer-induced sys-
temic inflammation [15].
Inflammation has been suggested to be involved in the
development of depression [16] and other psychiatric disor-
ders [17]. For instance, inflammatory cytokines have been
shown to influence neurocircuitry in the brain through the
consequence of neurotransmitter signaling [18], including a
cascade of behavioral and immune responses that might
lead to depression, anxiety [19], and PTSD [19, 20] among
vulnerable individuals. Although the link between inflam-
mation and psychiatric disorders has been less explored
among patients with cancer, chronic inflammatory disor-
ders have been reported to be risk factors for depression
and anxiety among cancer patients [21].
Non-steroidal anti-inflammatory drugs (NSAIDs) are
commonly prescribed for pain and inflammation. The
anti-inflammatory actions of NSAIDs include inhibition
of cyclooxygenase (COX) activity and prostaglandin syn-
thesis [22]. Due to its non-competitive and irreversible
acetylation of COX, aspirin is different from non-aspirin
NSAIDs in terms of indications and adverse effects [23].
A recent meta-analysis of 26 relatively small randomized
clinical trials suggested that NSAIDs play an antidepres-
sant role in patients with major depressive disorder and
are reasonably safe [24]. Preclinical studies indicate that
the use of aspirin is associated with a lower risk of de-
pression in the general population [25], and among pa-
tients with stroke [26] or osteoarthritis [27]. There is,
however, a lack of evidence in this regard among cancer
patients and on psychiatric disorders other than depres-
sion. Our recent preclinical study showed that low-dose
aspirin might counteract the inflammation-related cog-
nitive impairment in a mouse model of breast cancer
[28]. It is therefore plausible that aspirin may help to
prevent inflammation-related psychiatric disorders
among cancer patients.
To this end, we performed a nationwide register-based
study in Sweden to investigate the role of pre-diagnostic
use of NSAIDs, especially aspirin, in the risk of depres-
sion, anxiety, and stress-related disorders following can-
cer diagnosis. Our hypothesis was that pre-diagnostic
use of NSAIDs, especially aspirin, is associated with a
decreased risk of depression, anxiety, and stress-related




From the Swedish Cancer Register [29], we identified
338,009 patients that were diagnosed with a first primary
malignancy between July 1, 2006, and December 31,
2013. Through cross-linkages with the Swedish Causes
of Death Register, Migration Register, and Patient Regis-
ter, we followed these patients individually from the date
of cancer diagnosis until death, emigration from Sweden,
or 1 year after cancer diagnosis, whichever came first,
using the Swedish personal identity numbers. We fo-
cused on the first year after cancer diagnosis because the
risk of psychiatric disorders appears to be highest imme-
diately after cancer diagnosis [5]. Patients were excluded
from the analysis if they had conflicting information (i.e.,
died or emigrated before cancer diagnosis) (n = 982), or
were diagnosed at autopsy (n = 2336). Because we aimed
at assessing the risk of newly diagnosed psychiatric dis-
orders, patients with preexisting depression, anxiety, or
stress-related disorder before cancer diagnosis ascer-
tained since 1973 onward according to the Patient Regis-
ter [30] were also excluded (n = 17,787), leaving 316,904
patients in the final analysis (Fig. 1). We hypothesized
the newly onset depression, anxiety, and stress-related
disorders after cancer diagnosis might be more closely
related to cancer-related inflammation and the psycho-
logical stress patients experienced after receiving a can-
cer diagnosis.
Pre-diagnostic use of NSAIDs
We linked the cohort of cancer patients to the Swedish
Prescribed Drug Register, which contains information on
all prescribed medications that are dispensed in Sweden
since July 2005 [31]. The vast majority of prescribed medi-
cations are subsidized with a celling of co-payment in
Sweden. Medications are coded according to the Anatom-
ical Therapeutic Chemical (ATC) Classification System in
this register. We identified all records of NSAIDs (aspirin:
N02BA01, N02BA51, B01AC06; non-aspirin NSAIDs:
M01A) dispensed within 365 days before cancer diagnosis.
Patients were then classified into the mutually exclusive
categories “no use of NSAIDs,” “use of aspirin alone,” “use
of non-aspirin NSAIDs alone,” or “use of both.” We also
grouped the medications by cyclooxygenase selectivity.
Aspirin, flurbiprofen, ketoprofen, fenoprofen, tolmetin,
and oxaprozin were defined as COX-1 selective NSAIDs,
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whereas coxibs, meloxicam, etodolac, mefenamic acid,
and diclofenac were defined as COX-2 selective NSAIDs.
Nonselective NSAIDs and use of both categories were col-
lapsed into an additional group.
As aspirin is the most frequently used NSAID, and our
animal study suggested its protective role in cognitive well-
being in a mouse model of breast cancer [28], we specifically
studied aspirin and categorized the use of aspirin according
to recency of use, daily dose, and duration of use. Recency of
use was defined by the time between cancer diagnosis and
last dispensation during 365 days before cancer diagnosis,
and classified as “previous use” if the last dispensation was
more than 90 days before cancer diagnosis or “current use” if
no more than 90 days. The information of daily dose was ex-
tracted from the prescription text, and a mean daily dose
was calculated from the prescribed daily dose of each dispen-
sation. The daily dose was then categorized as low (20–150
mg), medium (151–300mg), or high (> 300mg). Duration of
use was defined as the number of days that patients were
supplied with aspirin, as estimated by the total dispensed
dose divided by the mean daily dose. We defined a patient as
a long-term user if the estimated duration was 300 days or
more (the median of all duration values). Possible regimens
of aspirin use, combining information on recency, dose, and
duration, were also examined.
Post-diagnostic depression, anxiety, and stress-related
disorders
Through the Patient Register, we identified all patients
with an inpatient or outpatient hospital visit that
resulted in a diagnosis of psychiatric disorders [Inter-
national Statistical Classification of Diseases and Related
Health Problems 10th Revision (ICD-10): F10-F99] dur-
ing the follow-up (from date of cancer diagnosis until up
to 1 year after cancer diagnosis). We then limited the
analysis to three groups of psychiatric disorders that are
common among cancer patients [32, 33] and potentially
related to inflammation [34], including (1) depression
disorders (ICD-10: F32, F33), (2) anxiety disorders (ICD-
10: F40, F41), and (3) stress-related disorders, namely
PTSD, acute stress reaction, adjustment disorder, and
other stress reactions (ICD-10: F43).
Covariables
Information on age at diagnosis, date of diagnosis, can-
cer type, and cancer stage was obtained from the Cancer
Register. We studied the most common cancer types, in-
cluding prostate cancer, breast cancer, gastrointestinal
cancers, lung cancer, skin cancer, kidney and bladder
cancers, gynecological cancers, hematological malignan-
cies, and other less common cancers including tumor of
the central nervous system. Using the European Net-
work of Cancer Registries Condensed TNM Scheme and
International Federation of Gynecology and Obstetrics
(FIGO) staging system, we classified non-hematological
malignancies as localized limited (T-localized/N0/M0 or
FIGO 0-I), localized advanced (T-advanced/N0/M0 or
FIGO II), regional spread (any T/N+/M0 or FIGO III),
distant metastasis (any T/any N/M+ or FIGO IV), and
unknown stage. “Mx” was regarded as “M0” because
Fig. 1 Flowchart of the study design. NSAIDs, non-steroidal anti-inflammatory drugs
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“Mx” is commonly used when there are no clinical indi-
cations of distant metastasis.
We calculated chronic disease score based on the
medications used during the year before cancer diagno-
sis, as a comorbidity measure [35, 36]. We excluded psy-
chiatric medications, anti-inflammatory drugs, and
analgesics from this calculation because they are related
to the outcome and exposure of interest in the present
study. We also ascertained potential indications for
NSAID use through the Patient Register and classified
them as cardiovascular diseases (ICD-10: G45.9, I00–02,
I05–09, I20–21, I30, I32–33, I38–40, I63, I65.2, I80–83,
I88, Z95), inflammatory musculoskeletal conditions
(ICD-10: M05–19, M45–46, M60, M65), inflammatory
systemic diseases (ICD-10: M30–36), and pain and fever
(ICD-10: F45.4, G43–44, G50.0–50.1, M25.5, M54.5,
M54.9, M79.1, N94.4, R50.8–50.9, R51–52). We further
linked the cohort to the Longitudinal Integrated Data-
base for Health Insurance and Labour Market Studies
(LISA) [37] for ascertainment of various potential con-
founders, including educational level, occupation, region
of residence (east, south, and north according to the
first-level Classification of Territorial Units for Statis-
tics), and marital status at cancer diagnosis.
Statistical analysis
We described baseline characteristics of the cancer pa-
tients according to their levels of NSAID use. We calcu-
lated the incidence rates (IRs) of depression, anxiety, and
stress-related disorders by diving the number of patients
that received a diagnosis of such disorders by the accu-
mulated number of person-years during follow-up. We
then investigated the rate of the studied disorders in re-
lation to the different levels of NSAID use using Cox
proportional hazards models. In the Cox models, the
“time to event” data were used by setting the date of
cancer diagnosis (from the Cancer Register) as the time
when an individual started being at risk for the outcome,
the date of diagnosis of depression, anxiety, or stress-
related disorder (from Patient Register) as the time of
event, and the earliest date among death (from the
Causes of Death Register), emigration (from the Migra-
tion Register), and 1 year after cancer diagnosis as the
time of censoring if no event happened. We adjusted for
age at cancer diagnosis, sex, calendar year of cancer
diagnosis, educational level, occupation, place of resi-
dence, marital status, and comorbidity in model 1 and
additionally adjusted for indications for NSAID use in
model 2. We created one dummy variable per indication
of NSAID use. In model 3, we further adjusted for can-
cer type and cancer stage. We first analyzed all studied
disorders together and then analyzed separately depres-
sion, anxiety, and stress-related disorders. We then fo-
cused on aspirin and studied the effect of recency of use,
daily dose, duration of use, and combined regimens of
aspirin use. To calculate stratum-specific HRs, we fitted
separate models for each level of sociodemographic fac-
tors, comorbidity, indications for use, and cancer charac-
teristics for aspirin use as well as for current, low-dose,
and long-term aspirin use. To test for effect modification
by these variables, we included interaction terms be-
tween NSAID use and these variables in the multivari-
able models and used Wald tests to test the statistical
significance of the estimated interaction terms (for one
exposure and one stratification variable at a time).
Because patients with other psychiatric disorders
might be more likely to use NSAIDs and at higher risk
of studied disorders after cancer diagnosis, we performed
a sensitivity analysis where cancer patients with any pre-
existing psychiatric disorders before cancer diagnosis
were excluded. Additionally, as patients with gastrointes-
tinal symptoms might avoid the use of NSAIDs and
might have a higher risk of depression, anxiety, and
stress-related disorders in general, we conducted another
sensitivity analysis where we stratified the analysis by
use of proton pump inhibitors, defined through at least
two dispensations, within 1 year before cancer diagnosis.
In all analyses, time since cancer diagnosis was used as
the underlying timescale. We used Schoenfeld residuals
to test the proportional hazards assumption for the main
exposure (i.e., NSAID use) in all models and found no
major deviation from the assumption.
The statistical analyses were performed using SAS,
version 9.4, SAS Institute and Stata, version 16, Stata-
Corp LP. We used a two-sided P < 0.05 to indicate statis-
tical significance.
Results
Among the 316,904 patients included in the analysis, the
median age at cancer diagnosis was 68 years and 53.4%
were male. 58,761 (18.5%) of these patients used aspirin
alone and 49,059 (15.4%) used non-aspirin NSAIDs
alone during the year before cancer diagnosis (Fig. 1).
Cancer patients who used aspirin alone were more likely
to be male, older, less educated, were less likely to be
working, had more comorbidities, and were more likely
to have a deceased partner, compared with patients who
did not use any NSAIDs (Table 1). Compared with no
users, aspirin users were more likely to have cardiovas-
cular disease, whereas non-aspirin NSAID users were
more likely to have inflammatory musculoskeletal condi-
tions such as arthritis.
Types of NSAID use and risk of depression, anxiety, and
stress-related disorders
A total of 5613 patients received a diagnosis of depres-
sion, anxiety, and stress-related disorders during the year
after cancer diagnosis. Compared with no NSAID use,
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Table 1 Baseline characteristics of cancer patients at the time of cancer diagnosis by exclusive use of NSAIDs
Characteristics No NSAIDs Aspirin Non-aspirin NSAIDs Both NSAIDs
Number 194,198 58,761 49,059 14,886
Year of cancer diagnosis (%)
2006–2009 86,249 (44.4) 26,731 (45.5) 23,287 (47.5) 7411 (49.8)
2010–2013 107,949 (55.6) 32,030 (54.5) 25,772 (52.5) 7475 (50.2)
Sex (%)
Male 99,678 (51.3) 36,861 (62.7) 23,780 (48.5) 8910 (59.9)
Female 94,520 (48.7) 21,900 (37.3) 25,279 (51.5) 5976 (40.1)
Age at cancer diagnosis, mean [SD], years (%) 65.7 [13.0] 75.4 [9.5] 64.8 [11.8] 73.3 [9.2]
Educational levela (%)
Low 63,369 (32.6) 27,762 (47.2) 15,859 (32.3) 6546 (44.0)
Medium 76,981 (39.6) 20,699 (35.2) 20,420 (41.6) 5590 (37.6)
High 51,399 (26.5) 9267 (15.8) 12,221 (24.9) 2513 (16.9)
Unknown 2449 (1.3) 1033 (1.8) 559 (1.1) 237 (1.6)
Occupation (%)
Blue-collar 28,227 (14.5) 2772 (4.7) 8472 (17.3) 901 (6.1)
White-collar 46,049 (23.7) 4163 (7.1) 10,959 (22.3) 1215 (8.2)
Not working 119,190 (61.4) 51,743 (88.1) 29,460 (60.1) 12,742 (85.6)
Unclassified or unknown 732 (0.4) 83 (0.1) 168 (0.3) 28 (0.2)
Region of residenceb (%)
East 71,206 (36.7) 19,957 (34.0) 17,831 (36.3) 4903 (32.9)
South 87,891 (45.3) 26,708 (45.5) 22,503 (45.9) 6834 (45.9)
North 35,101 (18.1) 12,096 (20.6) 8725 (17.8) 3149 (21.2)
Marital status (%)
Unmarried 29,383 (15.1) 4990 (8.5) 6355 (13.0) 1101 (7.4)
Married/registered partnership 108,123 (55.7) 31,120 (53.0) 28,141 (57.4) 8242 (55.4)
Divorced/separated 30,803 (15.9) 8474 (14.4) 8734 (17.8) 2441 (16.4)
Widow(er)/surviving partner 25,889 (13.3) 14,177 (24.1) 5829 (11.9) 3102 (20.8)
Chronic disease scorec (%)
0 80,567 (41.5) 25 (0.0) 15,061 (30.7) 19 (0.1)
1–3 95,079 (49.0) 25,849 (44.0) 29,061 (59.2) 5792 (38.9)
> 3 18,552 (9.6) 32,887 (56.0) 4937 (10.1) 9075 (61.0)
Diagnosis of potential indications for NSAIDsd (%)
Cardiovascular disease 30,121 (15.5) 28,326 (48.2) 7573 (15.4) 6823 (45.8)
Inflammatory musculoskeletal condition 28,002 (14.4) 10,981 (18.7) 14,905 (30.4) 4984 (33.5)
Inflammatory systemic disease 2792 (1.4) 1296 (2.2) 1135 (2.3) 462 (3.1)
Pain and fever 2410 (1.2) 630 (1.1) 1044 (2.1) 259 (1.7)
Cancer stagee (%)
Localized limited 57,011 (29.4) 14,106 (24.0) 13,274 (27.1) 3474 (23.3)
Localized advanced 11,719 (6.0) 3906 (6.6) 2328 (4.7) 743 (5.0)
Regional spread 20,914 (10.8) 5571 (9.5) 4730 (9.6) 1314 (8.8)
Distant metastasis 19,155 (9.9) 6317 (10.8) 5954 (12.1) 1934 (13.0)
Unknown 72,027 (37.1) 23,868 (40.6) 18,232 (37.2) 5929 (39.8)
Not applicablef 13,372 (6.9) 4993 (8.5) 4541 (9.3) 1492 (10.0)
Cancer typeg (%)
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the use of aspirin alone was associated with a lower rate of
the studied disorders in all models (HR, 0.88; 95% CI, 0.81
to 0.97 in model 3 with adjustment for sociodemographic
factors, comorbidity, indications, and cancer characteris-
tics) (Table 2). Similar results were found for depression,
anxiety, and stress-related disorders separately (Supple-
mentary Table S1). In contrast, the use of non-aspirin
NSAIDs alone was associated with an increased rate of the
studied disorders (Table 2 and Supplementary Table S1),
compared with no NSAID use. We did not find an associ-
ation between the use of both aspirin and non-aspirin
NSAIDs and the studied disorders. The sensitivity analyses
showed similar results after excluding patients with any
pre-existing psychiatric disorders (Supplementary Table
S2) or after stratifying the analysis by use of proton pump
inhibitors within 1 year before cancer diagnosis (Supple-
mentary Table S3).
A lower rate of depression, anxiety, and stress-
related disorders, although not statistically significant,
was suggested for use of COX-1 selective NSAIDs
(HR, 0.93; 95% CI, 0.85–1.01) compared with no
NSAID use (Supplementary Table S4). The use of
COX-2 selective NSAIDs was associated with a higher
rate (HR, 1.26; 95% CI, 1.15–1.38) of the studied dis-
orders compared with no NSAID use. A combined
use of COX-1 selective, COX-2 selective, and nonse-
lective NSAIDs was associated with a moderately in-
creased rate of the studied disorders.
Table 1 Baseline characteristics of cancer patients at the time of cancer diagnosis by exclusive use of NSAIDs (Continued)
Characteristics No NSAIDs Aspirin Non-aspirin NSAIDs Both NSAIDs
Prostate cancer 37,380 (19.2) 12,510 (21.3) 9699 (19.8) 3309 (22.2)
Breast cancer 30,135 (15.5) 4702 (8.0) 7484 (15.3) 1313 (8.8)
Gastrointestinal cancer 34,625 (17.8) 11,340 (19.3) 7029 (14.3) 2381 (16.0)
Lung cancer 11,126 (5.7) 4612 (7.8) 3867 (7.9) 1426 (9.6)
Non-melanoma skin cancer 11,619 (6.0) 5612 (9.6) 2190 (4.5) 1057 (7.1)
Melanoma 11,417 (5.9) 2242 (3.8) 2233 (4.6) 547 (3.7)
Kidney & bladder cancer 10,785 (5.6) 4764 (8.1) 2735 (5.6) 1155 (7.8)
Gynecological cancer 11,313 (5.8) 2438 (4.1) 2901 (5.9) 615 (4.1)
Hematological malignancy 13,372 (6.9) 4993 (8.5) 4541 (9.3) 1492 (10.0)
Other cancers 22,426 (11.5) 5548 (9.4) 6380 (13.0) 1591 (10.7)
Cancer patients were categorized into exclusive groups according to their usage of NSAIDs during the year before cancer diagnosis: non-users (never used any
NSAID), aspirin users (used aspirin but not non-aspirin), non-aspirin NSAID users (used non-aspirin NSAIDs but not aspirin), users of both NSAIDs (used both aspirin
and non-aspirin NSAIDs)
aClassified according to years of education: high (college and above), medium (9 years plus 2–3 years secondary school), low (9 years or less), or unknown
bIdentified through the First-level Classification of Territorial Units for Statistics, NUTS-1
cCalculated based on all medications used within 1 year before cancer diagnosis, after excluding psychiatric medications, anti-inflammatory drugs, and analgesics
from the original codes list that are directly related to the outcome or exposure of interest
dIdentified from the Swedish Patient Register since 2001. The four groups of potential indications are non-exclusive
eDefined by European Network of Cancer Registries Condensed TNM Scheme and International Federation of Gynecology and Obstetrics staging system: localized
limited (T-localized/N0/M0 or FIGO 0-I), localized advanced (T-advanced/N0/M0 or FIGO II), regional spread (any T/N+/M0 or FIGO III), distant metastasis (any T/any
N/M+ or FIGO IV), or unknown stage
fHematological malignancies were further divided into five subtypes: leukemia, lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative neoplasm
gDisplayed according to the most common cancer types in this population
Table 2 Hazard ratios (95% confidence intervals) of depression, anxiety, and stress-related disorders during the year after cancer
diagnosis, in relation to pre-diagnostic use of NSAIDs
Group 1000 PYs Event (IR) Model 1a Model 2b Model 3c
No NSAIDs 174 3408 (19.6) 1.00 1.00 1.00
Aspirin 50 797 (16.1) 0.88 (0.80–0.96) 0.86 (0.79–0.95) 0.88 (0.81–0.97)
Non-aspirin NSAIDs 43 1145 (26.4) 1.26 (1.18–1.35) 1.27 (1.18–1.36) 1.24 (1.15–1.32)
Both NSAIDs 13 263 (20.9) 1.05 (0.91–1.20) 1.04 (0.91–1.19) 1.05 (0.92–1.20)
Cancer patients with any diagnosis of depression, anxiety, or stress-related disorders, namely post-traumatic stress disorder, acute stress reaction, adjustment
disorder, or other stress reactions before cancer diagnosis were excluded from the analysis. IRs were calculated by dividing the number of patients that received a
diagnosis of depression, anxiety, and stress-related disorders by the number of person-years accumulated during follow-up. Multivariable Cox proportional hazard
models were used to estimate the hazard ratios and 95% confidence intervals in relation to exclusive NSAID use, using no use of NSAIDs as the reference
Abbreviations: PYs person-years, IR incidence rate per 1000 person-years
aEstimates were adjusted for age, sex, calendar year of cancer diagnosis, educational level, occupation, region of residence, marital status, and Chronic
Disease Score
bEstimates were additionally adjusted for potential indications for NSAID use
cEstimates were additionally adjusted for common cancer types and cancer stage, as well as subtypes of hematological malignancies (leukemia, lymphoma,
myeloma, myelodysplastic syndrome, or myeloproliferative neoplasm)
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Recency, daily dose, and duration of aspirin use
The association of aspirin with reduced rate of depression,
anxiety, and stress-related disorders was primarily noted
among current users (HR, 0.84; 95% CI, 0.75 to 0.93), low-
dose users (HR, 0.88; 95% CI, 0.80 to 0.98), and long-term
users (HR, 0.84; 95% CI, 0.76 to 0.94) (Table 3). Among
commonly combined regimens, individuals with a com-
bination of current, low-dose, and long-term aspirin use
had the lowest rate of the studied disorders after cancer
diagnosis (HR, 0.77; 95% CI, 0.68 to 0.87).
Subgroup analysis and effect modification
The magnitude of the inverse association of aspirin use
alone with the rate of depression, anxiety, and stress-
related disorders was greater among females than males,
among patients who lived in the east of Sweden than pa-
tients who lived in other parts of Sweden, among pa-
tients with cardiovascular disease than patients without
cardiovascular disease, and among breast cancer patients
than patients with other cancer types (all P values for
interaction < 0.05) (Table 4). The association did not,
however, differ by calendar period of cancer diagnosis,
age, educational level, marital status, occupation, comor-
bidity, other indications for NSAID use, or cancer stage.
Similar result patterns were found for current use, long-
term use, and low-dose use of aspirin.
Discussion
To the best of our knowledge, this nationwide register-
based cohort study is the first to examine the association
of prior NSAID use with the risk of depression, anxiety,
and stress-related disorders after cancer diagnosis. The
study included all patients with newly diagnosed cancer
in Sweden between July 2006 and December 2013 and
found that aspirin use, especially long-term and low-
dose use, shortly before cancer diagnosis was associated
with a reduced rate of depression, anxiety, and stress-
related disorders during the first year after cancer
Table 3 Hazard ratios (95% confidence intervals) of depression, anxiety, and stress-related disorders during the year after cancer
diagnosis in relation to pre-diagnostic exclusive use of aspirin, analysis by recency of use, daily dose, and duration of use
Characteristics 1000 PYs Event (IR) Model 1a Model 2b Model 3c
No NSAIDs (reference group) 174 3408 (19.6) 1.00 1.00 1.00
Recency of aspirin use
Previous 12 229 (19.1) 1.02 (0.89–1.18) 1.02 (0.88–1.18) 1.01 (0.88–1.17)
Current 38 568 (15.1) 0.82 (0.74–0.91) 0.81 (0.73–0.90) 0.84 (0.75–0.93)
Daily dose of aspirin use
Low-dose 40 659 (16.4) 0.87 (0.79–0.97) 0.87 (0.78–0.96) 0.88 (0.80–0.98)
Medium dose 6 90 (15.8) 0.95 (0.76–1.18) 0.94 (0.75–1.17) 0.96 (0.77–1.19)
High dose 1 18 (19.9) 1.17 (0.73–1.86) 1.16 (0.72–1.84) 1.17 (0.73–1.86)
Duration of aspirin use
Short-term 10 210 (20.6) 1.07 (0.93–1.25) 1.06 (0.92–1.24) 1.07 (0.92–1.25)
Long-term 37 557 (15.2) 0.83 (0.74–0.92) 0.82 (0.74–0.91) 0.84 (0.76–0.94)
Combined regimens
Previous, low-dose 10 195 (19.3) 1.03 (0.88–1.21) 1.02 (0.87–1.19) 1.02 (0.87–1.19)
Previous, medium-high dose 2 30 (17.8) 1.09 (0.75–1.57) 1.06 (0.74–1.53) 1.04 (0.72–1.49)
Current, low-dose, long-term 26 362 (14.2) 0.76 (0.67–0.86) 0.75 (0.66–0.85) 0.77 (0.68–0.87)
Current, low-dose, short-term 5 102 (22.1) 1.15 (0.94–1.41) 1.13 (0.92–1.38) 1.16 (0.94–1.42)
Current, medium-high dose, long-term 4 65 (15.5) 0.94 (0.73–1.21) 0.92 (0.71–1.18) 0.95 (0.74–1.23)
Current, medium-high dose, short-term 1 13 (18.1) 1.04 (0.60–1.80) 1.02 (0.59–1.76) 1.05 (0.61–1.82)
Recency was defined by the time since last dispensed date to cancer diagnosis and patients were classified into previous users (more than 90 days before cancer
diagnosis) and current users (within 90 days before cancer diagnosis). A total dispensed dose of aspirin, average daily dose, and number of days to be covered
were calculated according to prescription text. Average daily dose was then categorized as low (20–150 mg), medium (151–300 mg), and high (> 300 mg) dose.
Long-term users were defined as those who used aspirin for ≥ 300 days during the 365 days before cancer diagnosis. IRs were calculated by dividing the number
of patients that received a diagnosis of depression, anxiety, and stress-related disorders by the number of person-years accumulated during follow-up. Combined
regimens across recency, dose, and duration were also examined. Hazard ratios and 95% confidence intervals were estimated from separate Cox proportional
hazard models to assess the effect of recency, dose, and duration of use, as well as the six combined regimens of aspirin use, using no use of NSAIDs as
the reference
Abbreviations: PYs person-years, IR incidence rate per 1000 person-years
aEstimates were adjusted for age, sex, calendar year at cancer diagnosis, educational level, occupation, region of residence, marital status, and Chronic
Disease Score
bEstimates were additionally adjusted for potential indications for NSAID use
cEstimates were additionally adjusted for common cancer types and cancer stage, as well as subtypes of hematological malignancies (leukemia, lymphoma,
myeloma, myelodysplastic syndrome, or myeloproliferative neoplasm)
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Table 4 Hazard ratios (95% confidence intervals) of depression, anxiety, and stress-related disorders during the year after cancer
diagnosis in relation to pre-diagnostic exclusive use of aspirin, stratified analysis by different factors
Characteristics Any exclusive aspirin use Current aspirin Low-dose aspirin Long-term aspirin
Calendar year at cancer diagnosis
2006–2009 0.82 (0.71–0.95) 0.74 (0.63–0.87) 0.82 (0.70–0.97) 0.77 (0.65–0.92)
2010–2013 0.93 (0.82–1.06) 0.90 (0.78–1.04) 0.93 (0.81–1.06) 0.89 (0.77–1.03)
P for interaction 0.72 0.36 0.66 0.70
Sex
Male 0.96 (0.83–1.11) 0.92 (0.79–1.07) 0.97 (0.83–1.12) 0.90 (0.77–1.06)
Female 0.80 (0.70–0.92) 0.74 (0.63–0.86) 0.80 (0.69–0.93) 0.77 (0.65–0.90)
P for interaction < 0.01 < 0.01 < 0.01 0.01
Age at cancer diagnosis, years
< 50 0.80 (0.42–1.54) 0.80 (0.38–1.71) 0.86 (0.44–1.71) 0.87 (0.37–2.07)
50–59 0.89 (0.65–1.21) 0.79 (0.55–1.13) 0.87 (0.63–1.20) 0.71 (0.48–1.05)
60–69 0.89 (0.74–1.08) 0.88 (0.71–1.08) 0.91 (0.75–1.11) 0.84 (0.68–1.04)
≥ 70 0.90 (0.79–1.03) 0.84 (0.73–0.97) 0.91 (0.79–1.04) 0.89 (0.77–1.02)
P for interaction 0.82 0.92 0.93 0.32
Education level
Low 0.89 (0.76–1.03) 0.85 (0.72–1.01) 0.89 (0.76–1.05) 0.87 (0.74–1.03)
Medium 1.02 (0.87–1.20) 0.93 (0.78–1.12) 1.04 (0.88–1.23) 0.96 (0.80–1.15)
High 0.67 (0.53–0.84) 0.66 (0.51–0.85) 0.63 (0.49–0.81) 0.58 (0.45–0.77)
P for interaction 0.14 0.58 0.05 0.07
Marital status
Unmarried 0.72 (0.54–0.96) 0.76 (0.55–1.04) 0.78 (0.58–1.06) 0.72 (0.52–1.01)
Married/registered partnership 0.86 (0.74–0.99) 0.79 (0.67–0.93) 0.84 (0.72–0.98) 0.78 (0.66–0.91)
Divorced/separated 0.97 (0.78–1.20) 0.96 (0.75–1.22) 0.98 (0.78–1.23) 0.99 (0.77–1.26)
Widow(er)/surviving partner 0.97 (0.78–1.20) 0.88 (0.69–1.11) 0.98 (0.78–1.23) 0.95 (0.75–1.20)
P for interaction 0.82 0.78 0.76 0.27
Occupation
Blue-collar 0.89 (0.61–1.29) 0.80 (0.52–1.23) 0.88 (0.60–1.30) 0.86 (0.56–1.32)
White-collar 0.80 (0.58–1.11) 0.74 (0.51–1.07) 0.77 (0.55–1.09) 0.60 (0.40–0.91)
Not working 0.89 (0.80–1.00) 0.85 (0.75–0.95) 0.90 (0.81–1.01) 0.87 (0.77–0.97)
P for interaction 0.93 0.92 0.86 0.84
Place of residence
East 0.83 (0.71–0.97) 0.76 (0.64–0.91) 0.86 (0.73–1.01) 0.79 (0.67–0.94)
South 0.93 (0.81–1.08) 0.93 (0.79–1.10) 0.93 (0.80–1.09) 0.90 (0.76–1.06)
North 0.87 (0.69–1.12) 0.73 (0.56–0.97) 0.84 (0.65–1.09) 0.80 (0.61–1.05)
P for interaction < 0.01 < 0.01 0.01 0.01
Chronic disease score c
1–3 0.91 (0.79–1.04) 0.84 (0.72–0.98) 0.91 (0.79–1.05) 0.86 (0.74–1.01)
> 3 0.87 (0.75–1.00) 0.83 (0.71–0.97) 0.88 (0.75–1.02) 0.82 (0.70–0.96)
P for interaction 0.39 0.59 0.38 0.35
Cardiovascular disease
No 0.95 (0.84–1.07) 0.88 (0.76–1.01) 0.97 (0.85–1.10) 0.90 (0.78–1.03)
Yes 0.81 (0.68–0.95) 0.79 (0.66–0.94) 0.79 (0.66–0.93) 0.78 (0.66–0.93)
P for interaction 0.01 0.12 0.01 0.07
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diagnosis. Non-aspirin NSAID use, on the other hand,
was associated with a higher rate of depression, anxiety,
and stress-related disorders.
The different results for aspirin and non-aspirin NSAI
Ds are consistent with recent studies of depression in
the general population [25] and among patients with
stroke [26]. We further extended the knowledge to other
common psychiatric disorders, including anxiety and
stress-related disorders (namely PTSD, acute stress
reaction, adjustment disorder, and other stress reac-
tions). The different results for aspirin and non-aspirin
NSAIDs are also biologically plausible. Accumulating
evidence supports the role of COX-1 inhibition in at-
tenuating neuroinflammation, leading to protection
against inflammatory brain damage [28, 38, 39]. In con-
trast, COX-2 inhibitors have been shown to augment
nitro-oxidative and oxidative stress in the brain [40], and
to interfere with the resolution of inflammation by
Table 4 Hazard ratios (95% confidence intervals) of depression, anxiety, and stress-related disorders during the year after cancer
diagnosis in relation to pre-diagnostic exclusive use of aspirin, stratified analysis by different factors (Continued)
Characteristics Any exclusive aspirin use Current aspirin Low-dose aspirin Long-term aspirin
Inflammatory musculoskeletal condition
No 0.90 (0.81–1.01) 0.84 (0.74–0.95) 0.92 (0.82–1.03) 0.86 (0.76–0.97)
Yes 0.82 (0.66–1.02) 0.81 (0.64–1.03) 0.76 (0.60–0.96) 0.78 (0.61–0.99)
P for interaction 0.49 0.90 0.16 0.54
Inflammatory systemic disease
No 0.88 (0.80–0.97) 0.83 (0.74–0.93) 0.89 (0.80–0.98) 0.84 (0.75–0.94)
Yes 0.93 (0.51–1.69) 0.85 (0.43–1.67) 0.80 (0.41–1.57) 0.75 (0.37–1.54)
P for interaction 0.88 0.85 0.47 0.58
Pain and fever
No 0.88 (0.80–0.97) 0.83 (0.74–0.92) 0.88 (0.79–0.98) 0.84 (0.75–0.94)
Yes 0.98 (0.52–1.84) 1.04 (0.52–2.06) 0.92 (0.47–1.80) 0.61 (0.28–1.36)
P for interaction 0.90 0.66 0.98 0.42
Cancer stage
Localized limited 0.78 (0.63–0.95) 0.71 (0.56–0.89) 0.79 (0.64–0.97) 0.73 (0.58–0.92)
Localized advanced 1.06 (0.75–1.50) 1.12 (0.77–1.64) 0.95 (0.65–1.39) 0.82 (0.55–1.24)
Regional spread 0.78 (0.61–0.99) 0.72 (0.55–0.95) 0.77 (0.60–1.00) 0.73 (0.56–0.96)
Distant metastasis 1.01 (0.76–1.34) 0.98 (0.72–1.33) 1.10 (0.83–1.47) 1.08 (0.80–1.47)
P for interaction 0.57 0.45 0.23 0.14
Cancer type
Prostate cancer 0.94 (0.71–1.26) 0.88 (0.64–1.20) 0.93 (0.68–1.26) 0.77 (0.56–1.07)
Breast cancer 0.74 (0.56–0.98) 0.63 (0.46–0.87) 0.73 (0.54–0.97) 0.71 (0.52–0.98)
Gastrointestinal cancer 1.03 (0.84–1.27) 1.05 (0.84–1.32) 1.02 (0.82–1.27) 1.03 (0.82–1.29)
Lung cancer 0.78 (0.58–1.05) 0.70 (0.50–0.97) 0.82 (0.61–1.12) 0.73 (0.53–1.01)
Skin cancer excl. Melanoma 1.07 (0.66–1.74) 0.89 (0.52–1.53) 1.09 (0.65–1.84) 1.19 (0.71–1.99)
Melanoma 0.56 (0.30–1.03) 0.54 (0.28–1.05) 0.45 (0.23–0.91) 0.42 (0.20–0.89)
Kidney and bladder 0.86 (0.59–1.26) 0.80 (0.52–1.23) 0.85 (0.56–1.27) 0.92 (0.61–1.39)
Gynecologic cancer 0.76 (0.52–1.12) 0.83 (0.55–1.25) 0.78 (0.52–1.16) 0.68 (0.44–1.05)
Hematological malignancies 1.16 (0.82–1.66) 1.25 (0.85–1.83) 1.25 (0.87–1.80) 1.18 (0.79–1.76)
Other cancers 0.80 (0.62–1.05) 0.67 (0.49–0.91) 0.83 (0.63–1.09) 0.74 (0.55–1.01)
P for interaction 0.04 0.03 0.15 0.12
The columns refer to four definitions of exposure in separate models: any exclusive use of aspirin, current use of aspirin, low-dose use of aspirin, and long-term
use of aspirin, where no use of NSAIDs was used as the reference in all models. Stratum-specific hazard ratios were estimated for each exposure by fitting
separate Cox proportional hazard models for different levels of the stratification variable and are presented in different rows, adjusting for age, sex, calendar year
at cancer diagnosis, educational level, occupation, region of residence, marital status, Chronic Disease Score, potential indications for NSAIDs, cancer type, cancer
stage, and subtypes of hematological malignancies. To assess the interaction between the exposure and each stratification variable, multivariable models were
fitted adjusting for the above covariates and including an interaction term for the exposure and each level of the individual stratification variable. P for interaction
was then calculated through a Wald test of the null hypothesis that interaction parameter for the exposure and the individual stratification variable is equal to
zero. P < 0.05 indicates a statistically significant interaction between the exposure and the stratification variable
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decreasing the negative immunoregulator Prostaglandin
E2 [41], thereby aggravate neuroinflammation. Consistent
with this, selective COX-2 inhibitors have also been re-
lated to increased psychiatric symptoms including depres-
sion, anxiety, and changes in cognition [42]. Taken
together, COX-1, rather than COX-2 inhibition, might be
the key factor in blocking neuroinflammation [38]. Our
findings that COX-2 selective NSAID use was associated
with a higher risk of common psychiatric disorders com-
pared with nonselective NSAID use also supports this hy-
pothesis. Aspirin selectively inhibits COX-1, particularly at
a low dose [38]. As the majority of aspirin is used at low
dose, the observed protective effect of aspirin on the stud-
ied disorders is likely driven by COX-1 inhibition. The
null association of high-dose aspirin may on the other
hand be due to additional inhibition of COX-2 [25]. In
contrast, although non-aspirin NSAIDs have mixed select-
ivity, they are mostly selective for COX-2 inhibition or
non-selective, possibly leading to the observed harmful ef-
fect of non-aspirin NSAIDs on these psychiatric disorders.
This was however partly inconsistent with the findings of
a recent meta-analysis that found celecoxib to have an
antidepressant effect when added to traditional antide-
pressants [24]. One possible explanation for the contra-
dictory findings might be the fact that we studied newly
onset depression, anxiety, and stress-related disorders
after cancer diagnosis whereas Bai et al. studied the treat-
ment effort on prevalent depression [24].
We further found that current, long-term, and low-
dose aspirin use was associated with the lowest rate of
depression, anxiety, and stress-related disorders after
cancer diagnosis. Current and long-term aspirin use re-
flects persistent anti-inflammatory activity, in addition to
low-dose use with enhanced inhibition of COX-1. The
stratified results by cancer stage showed clear evidence
for an inverse association between aspirin and the stud-
ied disorders in most stages of cancer, apart from distant
metastatic cancer. Furthermore, the effect of aspirin was
more pronounced among females, in line with the pro-
posed female-specific impact of low-dose aspirin in anti-
inflammation [43]. The stronger association noted for fe-
males might alternatively be attributable to the stronger
findings among breast cancer patients, which corrobo-
rates with our preclinical findings using animal models
[28]. The underlying reasons for the stronger association
among patients with breast cancer, compared with pa-
tients with other cancers, remain unknown. This finding,
together with the fact that patients with breast cancer
have indeed the highest prevalence of depression among
patients of different cancer types [33], highlights a po-
tentially specific role of inflammation in breast cancer-
related depression [44].
The strength of the study includes the nationwide
population-based study design, independent collection of
information on drug exposures and psychiatric disor-
ders, the comprehensive information of covariables, and
thorough statistical analysis including multivariable ad-
justments for potential confounders. Common systemic
and random errors are therefore minimized. Some po-
tential limitations of the study should, however, still be
noted. The Prescribed Drug Register does not include
information on medications used over the counter or in
hospitals and nursing homes. We speculate however that
this is non-differential between individuals that would
later receive a cancer diagnosis and subsequently also a
diagnosis of depression, anxiety, and stress-related disor-
ders and individuals that would not receive a diagnosis
of psychiatric disorders after being diagnosed with can-
cer. Such misclassification would therefore most likely
have diluted the magnitude of the studied association.
Also, this should not have affected the results on aspirin
use greatly because low-dose aspirin is mostly prescribed
in Sweden [45]. Further, because of its observational na-
ture, residual confounding due to unknown and unmeas-
ured confounders may exist. Patients with a pre-existing
psychiatric disorder might be more likely to use NSAIDs
and at higher risk of depression, anxiety, and stress-
related disorders after cancer diagnosis. We therefore
excluded patients with any psychiatric disorders—in
addition to patients with depression, anxiety, and stress-
related disorders—prior to cancer diagnosis and ob-
served similar results. However, the exclusion of these
patients was likely incomplete because not all patients
with psychiatric disorders attend health care. Similarly,
we investigated the role of gastrointestinal symptoms,
which could indicate high stress levels and reduced
NSAID use, by stratifying the analysis by use of proton
pump inhibitors during the year before cancer diagnosis
and found again similar results.
Conclusions
Aspirin use, especially current, long-term, and low-dose
use, was associated with a decreased risk of depression,
anxiety, and stress-related disorders following cancer
diagnosis, while the use of non-aspirin NSAIDs was as-
sociated with an increased risk, compared with no use of
NSAIDs. Our findings call for pre-clinical research in
examining the underlying mechanisms of low-dose as-
pirin and depression, anxiety, and stress-related disor-
ders after cancer diagnosis and, if confirmed in further
studies, provide a rationale for randomized clinical trials.
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